Argan Inc SEC Filings

Form 144 filing for ARGAN INC (AGX) discloses a proposed sale of 15,000 common shares on the NYSE through Merrill Lynch with an aggregate market value of $4,186,350 and approximately 13,811,575 shares outstanding. The filing lists the acquisition of 32,206 shares on 06/11/2025 via a stock option from Cynthia A Flanders, with the acquisition settled on 06/11/2025 on a cashless basis. The intended approximate sale date is 10/02/2025.

The filing lacks the name of the person on whose account the securities will be sold and does not provide a filing date in the remarks section. It also states there were no securities sold in the past three months by the person for whose account the sale is reported.

James W. Quinn, a director of Argan Inc. (AGX), reported on Form 4 that he sold 13,444 shares of the issuer's common stock on September 30, 2025, at an average price of $269.12 per share. Following the sale, Mr. Quinn is reported to beneficially own 49,570 shares indirectly through the James W. Quinn 2025 GRAT No.1. The Form 4 is signed and dated October 1, 2025.

William F. Leimkuhler, a director of Argan Inc. (AGX), reported a sale of the issuer's common stock on October 1, 2025. The filing records a sale transaction with an average price of $274.73 per share and indicates the disposal of either 11,802 shares (table entry) or 11,806 shares (explanatory paragraph), with a reported remaining beneficial ownership of 38,834 shares following the transaction. The Form 4 is a routine Section 16 disclosure showing an open-market sale by an insider and lists the reporting persons Darien, CT address and role as a director. The filing does not include any option or derivative transactions.

ARGAN, Inc. (AGX) Form 4: The reporting person, John R. Jeffrey, Jr., sold 4,698 shares of ARGAN common stock on 09/29/2025 at an average price of $268.60 per share on the open market. After the sale he beneficially owns 4,556 shares directly and 8,000 shares indirectly through an IRA. The sale is reported on Form 4 and signed on 10/01/2025. The filing identifies Mr. Jeffrey as a director of the issuer and indicates the transaction was an open-market disposition.

ARGAN, Inc. (AGX) submitted a Form 144 notice disclosing a proposed sale of 13,444 shares of common stock through Allen & Company on the NYSE with an aggregate market value of $3,667,792.08. The filing lists total shares outstanding of 13,811,575 and an approximate sale date of 09/30/2025. The securities reported were acquired via equity grants and restricted stock on 06/21/2023 (5,000 shares), 06/14/2024 (5,852 shares) and 12/14/2024 (2,592 shares). The document also reports recent sales by James W. Quinn: 11,897 shares on 09/19/2025 for $3,101,904.81 and 4,660 shares on 09/22/2025 for $1,208,571. The filer affirms no undisclosed material adverse information.

Argan, Inc. (AGX) submitted a Form 144 notifying the SEC of a proposed sale of 11,802 common shares acquired by stock option exercise on 06/09/2025. The filing lists the broker as Fidelity Brokerage Services LLC and shows an aggregate market value of $3,228,909.00 based on outstanding shares of 13,811,575. The approximate date of sale is 09/29/2025 on the NYSE. The filer certifies there is no undisclosed material adverse information and reports no sales of issuer securities in the past three months.

Form 144 Notice — ARGAN INC (AGX) This filing notifies a proposed sale of 4,698 shares of common stock on 09/29/2025 through Charles Schwab & Co., Inc. The filing states the shares were acquired via equity grants and exercised as options on 04/25/2024 (2,402 shares) and 06/12/2024 (2,296 shares). Aggregate market value of the proposed sale is reported as $1,281,708.36 and the total shares outstanding is listed as 13,811,575. The filer also discloses a prior sale of 2,621 shares on 07/29/2025 with gross proceeds of $617,586.23. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Charles E. Collins IV, Chief Executive Officer of Argan, Inc. (AGX), reported option exercise and open-market sale on September 24, 2025. He exercised 5,000 shares from an option granted September 12, 2019, at an exercise price of $43.10 per share, and immediately sold 5,000 common shares on the open market at $267 per share. Following these transactions the Form 4 reports 26,006 shares beneficially owned after the exercise and 21,006 shares after the sale; the filing also records ownership of options underlying 5,000 shares and total derivative beneficial ownership of 39,735.

The Form 4 is signed and dated September 26, 2025, and identifies Collins as an officer (CEO). The filing documents standard Section 16 reporting of insider option exercise and subsequent disposition of shares.

Peter W. Getsinger, a director of Argan, Inc. (AGX), sold 1,000 shares of the company's common stock on September 19, 2025, on the open market at an average price of $264.54 per share. After the sale, Getsinger beneficially owned 11,896 shares directly. The Form 4 was signed on September 23, 2025, and lists Getsinger's Edgartown, MA address and director status. No derivative transactions or amendments are reported and the filing indicates this was a routine open-market disposition executed at the stated price.